[1] |
FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong.
Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
|
[2] |
LI Yingfen, HAN Lei.
Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
|
[3] |
LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong.
One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
|
[4] |
SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian.
Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
|
[5] |
HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia.
535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
|
[6] |
FAN Xiucong, DONG Xiaohui, CHEN Danxia, BAO Siwei, MA Yabin.
Pharmaceutical care of a patient with Clostridium difficile infection and urinary tract infection during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 579-582.
|
[7] |
LIU Bin, SHAO Meiling, CAI Yiran, MA Fengyi, LAN Hong.
Applicability of PDCA cycle in standardization of outpatient prescriptions
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1035-1039.
|
[8] |
YANG Jia, LI Gen, JIANG Yongxian, TAO Wanjun, CHEN Wenwen, LIANG Hua.
Infant ankle edema and lactic acid increase induced by diazoxide: a case study
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 789-791.
|
[9] |
MA Bingbing, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian, LYU Jintao.
Consideration of rational use of traditional Chinese medicine and pharmaceutical services for the elderly based on literature analysis
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 595-599.
|
[10] |
LI Xiaofei, CHENG Rong, WU Xuemei, LIU Zhi.
Safety of terlipressin for injection based on electronic medical records
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 654-656.
|
[11] |
CHEN Fangfang, ZHANG Hongxu.
Pharmacy practice during the treatment of primary central nervous system lymphoma with high dose methotrexate
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 446-449.
|
[12] |
JIN Haobin, ZHENG Lei, YANG Jing, GUAN Yuyao, ZHANG Xiaoli.
Adverse reactions of skin drugs and concomitant liver and kidney dysfunction in inpatients
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 310-312.
|
[13] |
LYU Juan, GUO Weiyan, WANG Yuanji, LI Yamei, WANG Yingli, DUAN Shiwan.
115 cases of drug-related adverse reactions in the liver
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 200-204.
|
[14] |
LU Song, YANG Ping, YANG Li, DONG Xianzhe, ZHANG Lan.
Research progress in human serum albumin injections
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 228-232.
|
[15] |
ZHANG Shuai, GENG Yue, WAN Liyan, JI Liwei.
Efficacy and safety of insulin degludec vs other long-acting basal insulin analogues in the treatment of type 1 diabetes
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1358-1361.
|